INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NasdaqGM: ACRX).
The investigation focuses on whether the Company and its executives violated federal securities laws by making materially false and misleading statements regarding the Company’s business, operations, and prospects.
On March 9, 2015, AcelRx announced that it has received correspondence from the United States Food and Drug Administration advising that, in addition to the bench testing and Human Factor studies it has performed for its drug Zalviso, the New Drug Application for Zalviso will require a new clinical study to assess the risk of inadvertent dispensing and the overall risk of dispensing failures.
Following this news, AcelRx stock declined by $3.23 per share, or nearly 37%, to close on March 9, 2015 at $5.51 per share.
If you invested in AcelRx stock or options through March 8, 2015 and would like to discuss your legal rights, please contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding AcelRx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.